Research Article
RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients
Figure 4
Kaplan-Meier plots of patients for progression-free survival (PFS) grouped by plasma KRAS and RAS/BRAF mutation status. The plasma KRAS mutations were not associated with shorter PFS (median PFS 239 days versus 443 days, ) (a). However, plasma RAS/BRAF mutations were associated with poor PFS compared to wild type (median PFS 239 days versus 443 days, , HR = 3.351) (b).
(a) |
(b) |